Hiteck (http://www.hiteck.com.cn/) is a Chinese biopharmaceutical company based in Wuhan and listed in Shenzhen Stock Exchange (Code 300683). It has one large molecule Class I drug (innovation product) on the Chinese market and another one completed phase III clinical trials earlier this year. It will soon be launched in China as well.Hiteck is investing one billion RMB (~$150 MM) to build up its small molecule API business unit focusing on generic API and CDMO, including RSM, GMP intermediates and proprietary APIs. Hiray is Hiteck's fully owned subsidiary with API manufacturing plant under construction a 200K square meter land in Jingmen, Hubei, about 250 km west of Wuhan. A multi-bay pilot plant will be operational in Q2 2021 and two commercial scale workshops, one for dedicated product and one multi-purpose, will be operational later in the year.Establishment of business development teams and process development teams will soon be underway